TNDM

$23.91

Post-MarketAs of Mar 17, 8:00 PM UTC

Tandem Diabetes Care, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$23.91
Potential Upside
5%
Whystock Fair Value$25.11
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-97.89%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.89

Recent News

StockStory
Mar 17, 2026

Why Are Tandem Diabetes (TNDM) Shares Soaring Today

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 7.8% in the afternoon session after investment firm Piper Sandler upgraded the stock to Overweight from Neutral and increased its price target.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Fly
Mar 17, 2026

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 16, 2026

1 Surging Stock with Impressive Fundamentals and 2 Facing Challenges

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

Assessing Tandem Diabetes Care (TNDM) Valuation After Android Expansion For Tandem Mobi

Android expansion opens new chapter for Tandem Diabetes Care (TNDM) Tandem Diabetes Care (TNDM) is back in focus after announcing that its Tandem Mobi automated insulin delivery system can now be controlled from compatible Android smartphones through the Tandem Mobi mobile app in the US. The Android rollout, which was cleared by the US Food and Drug Administration in November 2025 and initially released on a limited basis in December 2025, broadens access beyond iOS users and could influence...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

How Investors Are Reacting To Tandem Diabetes Care (TNDM) Expanding Mobi Control To Android Smartphones

In March 2026, Tandem Diabetes Care announced that its Tandem Mobi automated insulin delivery system can now be controlled via the Tandem Mobi mobile app on compatible Android smartphones in the U.S., following U.S. Food and Drug Administration clearance in November 2025 and a limited release in December 2025. This Android rollout meaningfully broadens access and convenience for Tandem Mobi users, strengthening Tandem Diabetes Care’s position in smartphone-based diabetes management...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.